Scivision Biotech (TPE:1786) Payments of Debt: NT$-0.5 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1786 Scivision Biotech Inc TPE:1786
76 GF Score
Price NT$49.95
GF Value NT$116.00
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Scivision Biotech Payments of Debt?

Scivision Biotech TPE:1786 -0.89% 76 Payments of Debt is NT$-0.5 Mil as of Dec. 2025. GuruFocus rates TPE:1786 with a GF Score™ of 76/100 and a GF Value™ of NT$116.00 (Possible Value Trap). The stock has 4 warning signs investors should review.

Scivision Biotech's Payments of Debt for the three months ended in Dec. 2025 was NT$-0.5 Mil.

Scivision Biotech's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.5 Mil.

Scivision Biotech Payments of Debt Related Terms

Scivision Biotech Payments of Debt Historical Data

* Premium members only.

The historical data trend for Scivision Biotech's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scivision Biotech Payments of Debt Chart

Scivision Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -910.00 -904.52 0.00 0.00 -1.49

Scivision Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.50
TPE:1786
76GF Score
Scivision Biotech Inc TPE:1786
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scivision Biotech Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of NT$-0.5 Mil mean?
Scivision Biotech (TPE:1786) has a Payments of Debt of NT$-0.5 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Scivision Biotech and its competitors.
Is Scivision Biotech's Payments of Debt too high?
Scivision Biotech's current Payments of Debt is NT$-0.5 Mil. Overall, Scivision Biotech has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's Payments of Debt compare to ISRG and BDX?
Scivision Biotech's Payments of Debt of NT$-0.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Devices & Instruments company?
A good Payments of Debt depends on the Medical Devices & Instruments industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Scivision Biotech and its competitors. Scivision Biotech's current Payments of Debt is NT$-0.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Possible Value Trap. The stock's GF Value™ is NT$116.00, compared to a current price of NT$49.95 — trading 56.9% below its estimated fair value. The current Payments of Debt is NT$-0.5 Mil. Scivision Biotech's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current Payments of Debt is NT$-0.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scivision Biotech (TPE:1786) Overvalued in 2026?

Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued. The current stock price of NT$49.95 is trading 56.9% below its estimated GF Value™ of NT$116.00. GuruFocus considers Scivision Biotech to be Possible Value Trap.

Key valuation signals for TPE:1786:

  • Payments of Debt: NT$-0.5 Mil
  • GF Value™: NT$116.00 vs. price of NT$49.95 (56.9% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scivision Biotech Business Description

Address No. 1, South 1st Road, Qianzhen District, Kaohsiung, TWN, 806
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
76GF Score

Get the complete analysis for TPE:1786

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.95
Price
NT$116.00
GF Value